XELOX

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study

QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer

LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis

Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Total Neoadjuvant Treatment Without Surgery For Locally Advanced Rectal Cancer

CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer

A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer

Perioperative FLOT vs Adjuvant XELOX for CA Stomach

KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer